Max Planck spin-off eversyn secures 1.6 million euros in seed capital
eversyn's technology could revolutionize the development of nutritional products and biopharmaceuticals
eversyn, a spin-off of the Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg, has successfully raised €1.6 million in seed capital to advance its innovative technology applications in the fields of nutrition and biopharmaceuticals.
This investment follows a €1.1 million grant from the EXIST research transfer program, a government funding initiative of the Federal Ministry of Economics and Climate Protection (BMWK) to support innovative start-ups. The financing round was led by bmp ventures with funding from IBG and included co-investments from the Max Planck Society, the Max Planck Foundation's MPF Start-Up Accelerator GmbH and a strategic business angel.
Facilitating access to high-quality, complex glycans
The nutrition and biopharma industry is experiencing unprecedented growth, driven by increasing health awareness, aging populations and the prevalence of non-communicable chronic diseases. eversyn's technology overcomes the limitations of traditional cell-based approaches in these industries. The start-up's cell-free enzymatic approach enables the optimization of complex biosynthetic pathways without the limitations of cellular metabolism. The technology enables the production of high-quality, complex glycans with unprecedented efficiency and flexibility and could revolutionize the development of nutritional products and biopharmaceuticals.
Dr. Thomas Rexer, CEO and co-founder of eversyn, said: "This funding round marks a pivotal moment in eversyn's development, providing us with the necessary resources to scale our production capabilities and bring our breakthrough technology to market faster. We are particularly excited about the opportunities it presents to address pressing challenges in the nutrition and biopharmaceutical sectors, where our solutions can create significant value for society. The support of Max Planck Innovation GmbH over the past years - in patenting, founding and attracting funding and investment - has been crucial for us to advance our mission. We could not have reached this point without the excellent support from the EXIST research transfer program, both in terms of funding and start-up advice."
Investor support and scientific guidance
The investment round received strong support from financial and scientific institutions and underlines the potential of eversyn's technology.
Philipp Kopp, Investment Manager at bmp Ventures, commented: "eversyn's innovative approach to nutrition and biopharmaceuticals addresses critical market needs with a scalable technology platform. The team's deep technical expertise and clear vision for commercialization were key factors in our investment decision."
Dr. Axel Nemetz, Managing Director of the MPF Start-up Accelerator: "We strongly believe in eversyn's vision and technology. The extensive patent portfolio significantly reduces the manufacturing costs for essential glycan building blocks - by almost an order of magnitude. This enables unprecedented commercial feasibility for the production of key components needed in biopharmaceuticals and nutrition to accelerate the development of next-generation therapeutics and human milk oligosaccharides for infant formula. The breakthrough approach in life sciences fits perfectly with our commitment to invest in transformative, science-based companies. We are excited to support the growth of eversyn and contribute to the future of this exceptional international team that has emerged from a leading Max Planck Institute."
Technology transfer through basic research
eversyn is a spin-off of the Max Planck Institute for Dynamics of Complex Technical Systems in Magdeburg. The institute is dedicated to all aspects of process systems technology that are of crucial importance for the future well-being of global society. The emergence of the company from the institute underlines the potential of basic research to promote technological progress and economic growth through technology transfer and commercialization.
Dr. Lars Cuypers, Senior Patent & Licensing Manager, and Sebastian Meyer-Borchert, Senior Start-up & Portfolio Manager at Max Planck Innovation: "eversyn is a prime example of how groundbreaking basic research can develop into a promising start-up. The team has succeeded in transforming a complex scientific concept into a viable business model with significant application examples. With its innovative technology platform, eversyn not only brings scientific knowledge to industry, but also demonstrates how effectively knowledge transfer can lead to impactful start-ups. We are proud to have accompanied the team from the initial IP strategy to the successful completion of this financing round."
Looking ahead
With the new funding, eversyn will expand its production capacity, grow its team, intensify its ongoing research and development activities and forge strategic partnerships. These initiatives will accelerate market entry and position eversyn as a key innovator in nutrition and biopharmaceutical solutions. The company remains committed to delivering impactful technologies to address critical global health challenges.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department science
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.